The Pharma Letter M&A roundup - September 2023

6 October 2023
merger_deal_stock_2022_large

Pharma's biggest companies were inactive during September's M&A market.

Just four deals were reported on by The Pharma Letter in total, a 66% reduction on the 12 of the previous month.

Perhaps the most interesting acquisition of September was Italy-based Alfasigma buying Intercept Pharmaceuticals (Nasdaq: ICPT), a US biopharma that once appeared to be in pole position to reach western markets with the first treatment for non-alcoholic steatohepatitis (NASH), but has since suffered numerous share-busting setbacks with its candidate obeticholic acid.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical